CURRENT RESEARCH STUDIES

ARISTOTLE CV 185-030

• Bristol-Myers Squibb Pharmaceutical Research Institute
• Apixiban for Reduction In Stroke and Other ThromboemboLic Events in atrial fibrillation
• Phase 3, Active(Warfarin) controlled, randomized double-blind, parallel arm study to evaluate the efficacy and safety of Apixiban in preventing stroke and systemic embolism in subjects with nonvalvular atrial fibrillation.

AVERROES CV 185-048

• Bristol-Myers Squibb Cardiovascular Clinical Research. McMaster University, Hamilton
• Apixiban VErsus asa to Reduce the Rate Of Embolic Stroke
• Apixiban vs ASA to prevent stoke in subjects with atrial fibrillation who failed or are unsuitable for Coumadin (warfarin)

AVANTE-GARDE TIMI 43 CSPP100A2347

• Novartis - Harvard Medical School.
• Double blind, parallel group, multinational clinical trial to evaluate the efficacy of Aliskiren and VAlsartan versus placebo in lowering levels on NT-proBNP in stable subjects post acute coronary syndrome.

CASSIOPEA EFC6034

• Sanofi-Aventis Research and Development
• Clinical study Assessing SSR126517E Injections Once weekly in Pulmonary Embolism therapeutic Approach
• An international, double-blind double-dummy, parallel group study of 3 month or 6 month treatment with SSR126517E vs. oral INR-adjusted Warfarin treatment of subjects with systemic pulmonary embolism with or without DVT. 48 hour enrolment window.

REDEEM 1160-67

• Boehringer Ingelheim
• Uppsala Clinical Research Centre University Hospital
• Randomized Dobigatran Etexitale dose finding study in patient with acute coronary syndromes post index Event with additional risk factors for cardiovascular complications also receiving aspirin and plavix: Multicentre.

ROCKET BAY 597939

• Phase III, multicentre, randomized, double-blind, double-dummy, parallel group, non-inferiority Trial comparing the Efficacy and safety of once daily oral rivaroxaban with adjusted dose oral warfarin for the prevention of stroke and non central nervous system embolism in patients with non valve atrial fibrillation

TRA 2P TIMI 50

• Schering-Plough Research Institute . Montreal Heart institute and Harvard Medical School.
• Thrombin Receptor Antagonist in Secondary Prevention of atherothrombotic ischemic events
• Multicentre, randomized, double-blind, placebo-controlled study to evaluate teh safety and efficacy of SCH 530348 in addition to standard care in subjects with a history of atherosclerotic disease

f you are interested in participating in a clinical trial please download and complete the Research study questionnaire and mail it to us or Fax to 905 721 8564 or contact our Research study coordinators at 905 721 1999 ext 228 or come to Heart Care Clinic during regular business hours. You will have full evaluation by our Research group with no obligation or at any cost to you.

If you have been recently diagnosed with ATRIAL FIBRILLATION OR SUFFERED A HEART ATTACK OR STROKE WITHIN LAST ONE YEAR OR SURGERY FOR BLOCKED ARTERIES IN LEG OR SUFFER FROM LEG PAINS BECAUSE OF BLOCKAGES / POOR CIRULATION YOU MAY BE ELIGIBLE TO PARTICIPATE IN A CLINICAL TRIAL AND HAVE THE OPPORTUNITY OF TREATMENT WITH NEWER MEDICATIONS. OUR CLINICAL TRIALS OUR IN COLLABORATION WITH HARVARD MEDICAL SCHOOL (TIMI), McMASTER UNIVERSITY, MONTREAL HEART INSTITUTE AND OTHER LEADING ACADEMIC CENTRES